Smart Measurement of Circulating Tumor DNA

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorErasmus Medical Center

About this trial

The goal of this study is to develop a blood-test which can detect colorectal cancer in early stages.

Participants will be asked to take an extra blood test, which will be analyzed further in the lab.

Eligibility criteria

Qualifiers

Have proven Lynch Syndrome (MMR-gene or EPCAM mutation), or have a proven microsatellite instability high (MSI-H)tumor;

Are at least 18 years old; Have been diagnosed with any form of cancer at the time of inclusion, but have had no treatment yet;

Have granted informed consent to participate in this study.

Disqualifiers

Are unwilling to undergo extra blood sampling;

Are under the age of 18;

Have no newly diagnosed tumors at time of inclusion;

Have been treated for their tumor at time of inclusion;

Trial design

Treatments tested in this trial

  • Blood Product

Treatment groups

50 Participants
are divided into 1 treatment group

Sponsors and collaborators

Erasmus Medical Center

Lead sponsor

Dutch Cancer Society

Collaborator

Leiden University Medical Center

Collaborator